JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kern, S. E.
Right arrow Articles by Yaksh, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kern, S. E.
Right arrow Articles by Yaksh, T.
Related Collections
Right arrow Regional Anesthesia
Right arrow Pain
Right arrow Pharmacology

Anesth Analg 2007;104:1514-1520
© 2007 International Anesthesia Research Society
doi: 10.1213/01.ane.0000262038.58546.e6

PAIN MEDICINE

The Pharmacokinetics of the Conopeptide Contulakin-G (CGX-1160) After Intrathecal Administration: An Analysis of Data from Studies in Beagles

Steven E. Kern, PhD*, Jeff Allen, PhD{dagger}, John Wagstaff, PhD{ddagger}, Steven L. Shafer, MD§, and Tony Yaksh, PhD{dagger}

From the *Department of Pharmaceutics & Anesthesiology, University of Utah, Salt Lake City, Utah; {dagger}Department of Anesthesiology, University of California at San Diego, San Diego, California; {ddagger}Cognetix, Inc., Salt Lake City, Utah; and §Department of Anesthesiology, Stanford University, Palo Alto, California.

Address correspondence and reprint requests to Steven E. Kern, PhD, Department of Pharmaceutics, University of Utah, 421 Wakara Way #318, Salt Lake City, Utah 84108. Address e-mail to Steven.Kern{at}hsc.utah.edu.

BACKGROUND: The synthetic peptide agent Contulakin-G (CGX-1160), isolated from the toxin of the snail Conus Geographus, produces significant analgesia in animals. Its peptide structure requires intrathecal administration for effectiveness, therefore we determined the intrathecal pharmacokinetics of CGX-1160 after bolus dose and multiple day infusions to beagles.

METHODS: For the bolus dose study, eight animals received a dose ranging from 16.7 to 1000 nmol under isoflurane anesthesia. Cerebral spinal fluid sampling for drug assay occurred up to 24 h. For the multiple day infusion study, three animals received infusions of 10, 40, and 160 µg/h respectively for 24 h at each rate. Cerebral spinal fluid sampling occurred during the infusion rate and the washout period after the 72 h of cumulative drug delivery. Data from the two study designs were modeled separately using NONMEM.

RESULTS: The results showed a biexponential disposition profile for both experiments with a rapid rate constant that was an order of magnitude greater than the slow rate constant. The bolus results showed a nonlinear dependence of the slow rate constant on administered dose due to the large bolus range used in the study.

CONCLUSION: These data, coupled with clinical pharmacology results, provide a basis for determining appropriate dosing strategies to achieve therapeutic intrathecal concentrations of Contulakin-G.






Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2007 by the International Anesthesia Research Society.